This pilot study evaluated the safety profile of intravenously administered BPC157 in human subjects. The research found that intravenous BPC157 infusion was well-tolerated with no serious adverse events reported in the study population. This evidence comes from a human clinical pilot study, representing preliminary safety data for this intervention.